Microbix Biosystems Inc. announces that it expects to file the financial statements and management disclosure and analysis for its third quarter of fiscal 2024 ended June 30, 2024 (“Q3 2024”) prior to the start of trading on August 14, 2024.

Microbix Biosystems Inc. introduces a novel Quality Assessment Product (QAP™) for Hepatitis C Virus (HCV) POCTs at the ADLM conference. This swab-based, room-temperature stable control aims to enhance accessibility and accuracy of HCV testing, especially in low-resource settings.

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces its hosting of Associate Minister of Small Business of Ontario, the Honourable Nina Tangri, to celebrate the opening of two expansions to its medical devices manufacturing capacity at one of its three adjacent Mississauga sites.

Microbix is a global leader in the production of native Antigens – preparations of purified and inactivated bacteria and viruses essential for the manufacture of “immunoassays.”